Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma
Open Access
- 1 June 2017
- journal article
- case report
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (25) , e7196
Abstract
BRAF and MEK inhibitors have significantly improved the prognosis of metastatic melanoma, by inhibiting both the mitogen-activated protein kinase (MAP-kinase) pathway. They are associated with infrequent adverse kidney events. Most of these are related to the use of BRAF inhibitors and involve interstitial nephritis with acute tubular necrosis. We report a unique case of glomerulonephritis with renal granulomatous vasculitis in a patient diagnosed with metastatic melanoma treated with BRAF and MEK inhibitors. The patient was a 55-year old woman, who presented a melanoma of the right thigh with pulmonary metastasis. Treatment started in November 2015, with Encorafenib and Binimetinib, new BRAF and MEK inhibitors, respectively. Two months after the beginning of the treatment, there was a worsening of her renal function with significant proteinuria. Kidney biopsy showed extracapillary proliferation in the glomeruli with a granulomatous reaction. Renal function recovered completely after withdrawal of the chemotherapy. All the reported kidney adverse events secondary to BRAF and MEK inhibitors in the literature are related to the use of BRAF inhibitors. Some previous reported mechanistic investigations also provide insight between BRAF inhibitors and podocytes injuries. Therefore, encorafenib most likely is the main responsible of the disease. However, evidence has emerged that inhibition of the MAP kinase pathway could also enhance autoimmunity. Thus, binimetinib may also have played a role and the combination of BRAF and MEK inhibitors may have facilitated this autoimmune kidney disease.Keywords
This publication has 14 references indexed in Scilit:
- BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic SyndromeAmerican Journal of Kidney Diseases, 2017
- Systemic vasculitis associated with vemurafenib treatmentMedicine, 2016
- New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanomaCancer Chemotherapy and Pharmacology, 2016
- Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patientsCancer, 2014
- Biological challenges of BRAF inhibitor therapyMolecular Oncology, 2011
- Mutational analysis of the PLCE1 gene in steroid resistant nephrotic syndromeJournal of Medical Genetics, 2010
- Key role of ERK pathway signaling in lupusAutoimmunity, 2009
- Identification of BRAF as a new interactor of PLCε1, the protein mutated in nephrotic syndrome type 3American Journal of Physiology-Renal Physiology, 2008
- Rapidly progressive crescentic glomerulonephritisKidney International, 2003
- Hydralazine may induce autoimmunity by inhibiting extracellular signal–regulated kinase pathway signalingArthritis & Rheumatism, 2003